Table 1 Characteristics of infants receiving at least one dose of palivizumab, by eligibility criteria
Characteristic | Infants receiving palivizumab | |||||||
|---|---|---|---|---|---|---|---|---|
Criterion 1 (N = 175/803) | Criterion 2 (N = 25/174) | Criterion 3 (N = 67/1804) | Other (N = 24/21,650) | |||||
n | (%) | n | (%) | n | (%) | n | (%) | |
Sex | ||||||||
Males | 94 | (53.7) | 17 | (68.0) | 44 | (65.7) | 16 | (66.7) |
Females | 81 | (46.3) | 8 | (32.0) | 23 | (34.3) | 8 | (33.3) |
Year of birth | ||||||||
2002–2009 | 17 | (9.7) | < 5 | (< 20.0) | 30 | (44.8) | 5 | (20.8) |
2010–2013 | 158 | (90.3) | < 25 | (< 100.0) | 37 | (55.2) | 19 | (79.2) |
Indigenous status | ||||||||
Aboriginal | 20 | (11.4) | 25 | (100.0) | 6 | (9.0) | < 5 | (< 20.8) |
Non-Aboriginal | 155 | (88.6) | 0 | – | 61 | (91.0) | < 24 | (< 100.0) |
Gestational age | ||||||||
< 28 weeks | 175 | (100.0) | 25 | (100.0) | 12 | (17.9) | 16 | (66.7) |
28–32 weeks | 0 | – | 0 | – | 13 | (19.4) | < 5 | (< 20.8) |
33–36 weeks | 0 | – | 0 | – | 12 | (17.9) | < 5 | (< 20.8) |
≥ 37 weeks | 0 | – | 0 | – | 30 | (44.8) | 5 | (20.8) |
Birth weight | ||||||||
< 1500 g | 175 | (100.0) | 25 | (100.0) | 24 | (35.8) | 17 | (70.8) |
1500–2499 g | 0 | – | 0 | – | 13 | (19.4) | < 5 | (< 20.8) |
2500–2999 g | 0 | – | 0 | – | 11 | (16.4) | < 5 | (< 20.8) |
3000–3499 g | 0 | – | 0 | – | 11 | (16.4) | < 5 | (< 20.8) |
≥ 3500 g | 0 | – | 0 | – | 8 | (11.9) | < 5 | (< 20.8) |
Geographical area of birth* | ||||||||
Metropolitan | 125 | (71.4) | < 5 | (< 20.0) | 52 | (77.6) | 18 | (75.0) |
Rural | 35 | (20.0) | < 10 | (< 40.0) | < 15 | (< 22.4) | < 10 | (< 41.7) |
Remote | 14 | (8.0) | 12 | (48.0) | < 5 | (< 7.5) | < 5 | (< 20.8) |
Major congenital anomalies | ||||||||
Yes | 77 | (44.0) | 16 | (64.0) | 40 | (59.7) | 7 | (29.2) |
No | 98 | (56.0) | 9 | (36.0) | 27 | (40.3) | 17 | (70.8) |
Congenital heart disease | ||||||||
Yes | 157 | (89.7) | 18 | (72.0) | 67 | (100.0) | 0 | – |
No | 18 | (10.3) | 7 | (28.0) | 0 | – | 24 | (100.0) |
Chronic lung disease | ||||||||
Yes | 175 | (100.0) | 20 | (80.0) | 15 | (22.4) | < 5 | (< 20.8) |
No | 0 | – | 5 | (20.0) | 52 | (77.6) | < 24 | (< 100.0) |
Season of birth | ||||||||
Spring | 23 | (13.1) | < 5 | (< 20.0) | 13 | (19.4) | < 5 | (< 20.8) |
Summer | 30 | (17.1) | < 5 | (< 20.0) | 12 | (17.9) | < 5 | (< 20.8) |
Autumn | 66 | (37.7) | 10 | (40.0) | 24 | (35.8) | 10 | (41.7) |
Winter | 56 | (32.0) | 9 | (36.0) | 18 | (26.9) | 11 | (45.8) |
Multiple birth | ||||||||
Singleton | 135 | (77.1) | < 25 | (< 100.0) | 60 | (89.6) | < 24 | (< 100.0) |
Multiple | 40 | (22.9) | < 5 | (< 20.0) | 7 | (10.4) | < 5 | (< 20.8) |
Number of previous pregnancies | ||||||||
0 | 62 | (35.4) | 9 | (36.0) | 18 | (26.9) | 8 | (33.3) |
1 | 41 | (23.4) | < 5 | (< 20.0) | 23 | (34.3) | 6 | (25.0) |
2 | 19 | (10.9) | < 5 | (< 20.0) | 8 | (11.9) | < 10 | (< 41.7) |
≥ 3 | 53 | (30.3) | 11 | (44.0) | 18 | (26.9) | < 5 | (< 20.8) |
Socioeconomic status | ||||||||
0–10% (most dis) | 29 | (16.6) | 7 | (28.0) | 9 | (13.4) | < 5 | (< 20.8) |
10–25% | 18 | (10.3) | < 10 | (< 40.0) | 10 | (14.9) | 7 | (29.2) |
25–75% | 96 | (54.9) | < 5 | (< 20.0) | 28 | (41.8) | 9 | (37.5) |
75–90% | 13 | (7.4) | 0 | – | < 15 | (< 22.4) | < 5 | (< 20.8) |
90–100% | 8 | (4.6) | 0 | – | < 5 | (< 7.5) | < 5 | (< 20.8) |
Missing | 11 | (6.3) | 7 | (28.0) | 0 | – | 0 | – |
Mother smoking during pregnancy | ||||||||
Yes | 29 | (16.6) | 13 | (52.0) | 9 | (13.4) | 5 | (20.8) |
No | 146 | (83.4) | 12 | (48.0) | 58 | (86.6) | 19 | (79.2) |